SurvivorNet on MSN

Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
MyChesCo on MSN

FDA clears five-minute lung cancer shot, redefining EGFR treatment

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...
WebMD

Uzedy: FDA Approves Once-a-Month Subcutaneous Injectable Risperidone for Bipolar I Disorder

What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...
clinicaladvisor.com

FDA Approves Subcutaneous Tremfya Induction Treatment for Ulcerative Colitis

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...
MedPage Today

Blockbuster Cancer Drug Can Now Be Administered More Easily

The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
Seeking Alpha

Merck wins FDA approval for subcutaneous Keytruda

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...
FiercePharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
EurekAlert!

PALOMA-2 study: Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

(Barcelona, Spain--September 9, 2025 at 11:30 AM CEST / UTC +2)— A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in ...
Healio

FDA approves Leqembi at-home subcutaneous injection in early Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
McKnight's Long-Term Care News

FDA OKs subcutaneous lecanemab injection for maintenance dosing for early Alzheimer’s

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
MedPage Today

Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...